Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients
E. Mazzone, R. De Sanctis, L. Fanelli, F. Bianco, M. Main, M. van den Hauwe, M. Ash, R. de Vries, J. Fagoaga Mata, K. Schaefer, A. D’Amico, G. Colia, C. Palermo, M. Scoto, A. Mayhew, M. Eagle, L. Servais, M. Vigo, A. Febrer, R. Korinthenberg, M. Jeukens M. de Viesser, A. Totoescu, T. Voit, K. Bushby, F. Muntoni, N. Goemans, E. Bertini, M. Pane, E. Mercuri.
Neuromuscul Disord. 2014. 24:347-352.
Evaluation of the correlation between the Hammersmith Functional Motor Scale and the MFM-20 in non-ambulant SMA children and adults at baseline, and over a 12 months period. Seventy-four patients performed both measures at baseline and 49 also had an assessment 12 months later. The correlation between the two scales was 0.733. The 12 month changes ranged between [1]11 and 4 for the Hammersmith and between [1]11 and 7 for the MFM-20. The results suggest that both scales provide useful information although they appeared to work differently at the two extremes of the spectrum of abilities. Hammersmith appeared to be more suitable in strong non ambulant patients, while the MFM-20 appeared to be more sensitive in the very weak patients.
Keywords: Outcome measures, Spinal muscular atrophy
Articles dans les revues scientifiques
Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: A cohort study
Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, Ropars J, Chouchane M, Cuppen I, Hughes I, Illingworth M, Marini-Bettolo C, Rambaud J, Taytard J, Annoussamy M, Scoto M, Gidaro T, Servais L. Neurology. 2018. 91(14), e1312-e1318. The study...
Functional assessment tools in children with Pompe disease: A pilot comparative study to identify suitable outcome measures for the standard of care
Ricci F, Brusa C, Rossi F, Rolle E, Placentino V, Berardinelli A, Pagliardini V, Porta F, Spada M, Mongini T. Eur J Paediatr Neurol 2018. 22(6),1103-1109. Progression of Pompe disease was evaluated in 8 young patients. From the results of the study, the authors...
Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)
Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL. BMJ Open. 2018. 30;8(7):e019932. Protocol of the "SPACE" in wich MFM is used as an outcome measure....
Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study
Chabanon A, Seferian AM, Daron A, Péréon Y, Cances C, Vuillerot C, De Waele L, Cuisset JM, Laugel V, Schara U, Gidaro T, Gilabert S, Hogrel JY, Baudin PY, Carlier P, Fournier E, Lowes LP, Hellbach N, Seabrook T, Toledano E, Annoussamy M, Servais L; NatHis-SMA study...
Mathematical Disease Progression Modeling in Type 2/3 Spinal Muscular Atrophy
Jacqmin P, Gieschke R, Delor I, Snoeck E, Vianna E, Vuillerot C, Sanwald Ducray P.Muscle Nerve. 2018. 58(4):528-535. Presentation of a mathematical model that empirically describes the development and deterioration of muscle function assessed by the 3 domains of MFM...
Is Going Beyond Rasch Analysis Necessary to Assess the Construct Validity of a Motor Function Scale?
Guillot T, Roche S, Rippert P, Hamroun D, Iwaz J, Ecochard R, Vuillerot C; the MFM Study Group. Arch Phys Med Rehabil. 2018. 99(9), 1776-1782.e9. Comparison of the fit quality of the confirmatory factor analysis (CFA) and the Rasch models on MFM item scores in...